The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Fri, 16th Apr 2021 15:17

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Tesco PLC - Welwyn Garden City, England-based grocer - Chair John Allan buys 44,426 shares at GBP2.25, worth GBP100,000 on Wednesday. Non-Executive Director Steve Golsby buys 8,608 shares at GBP2.25, worth GBP19,393, on Thursday.

----------

Dechra Pharmaceuticals PLC - Cheshire-based veterinary products - Tony Griffin, managing director of Dechra Veterinary Products EU, sells 25,000 shares at GBP38.52, worth GBP962,950, on Friday. Dechra says Griffin's sale is to widen his investment portfolio for long-term financial planning purposes. He continues to hold 45,650 shares.

----------

OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - Non-Executive Director Stephen Hammond buys 25,000 shares at 51.8 pence, worth GBP12,950, on Thursday. The purchase is his only holding, having joined the board in February. Hammond is a UK member of Parliament.

----------

4D Pharma PLC - Leeds-based live biotherapeutic products - Chief Executive Officer Duncan Peyton and Chief Scientific Officer Alex Stevenson take part in company's USD25.0 million equity raise in March. Peyton and Stevenson each subscribe for 658,840 shares at GBP1.10, together worth GBP1.4 million. Peyton now has 9.5 million shares, a 5.3% stake, and Stevenson 9.4 million.

----------

Power Metal Resources PLC - metals exploration and development in Africa, US and Canada - Chief Executive Paul Johnson buys 500,000 shares at 2.39p each, GBP11,957 in total, on Thursday. Johnson had bought another 500,000 shares on Thursday that was already reported, for a GBP23,452 total investment. He now has 62.5 million shares, a 5.5% stake.

----------

Parsley Box Group PLC - Edinburgh-based ready-meal deliveries - Non-Executive Chair Chris van der Kuyl and wife Heather buy 26,165 shares at GBP1.86 to GBP2.03, worth about GBP50,000, on April 1 and April 12. Van der Kuyl now holds 2.3 million shares directly and 1.6 million indirectly via 4J Studios Ltd, for a 9.4% total stake. Parsley listed on AIM on March 31 at an initial public offering price of 200p.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Non-Executive Director Mark Ward buys 171,242 shares at 40.7p, worth GBP69,695, on Thursday. Ward now has 2.3 million shares, a 13.5% stake. He also has agreed to subscribe to 1.4 million new shares as part of InnovaDerma's placing announced back in January. Finance Director Andrew Dunderdale buys 24,937 shares at 40.1p, also on Thursday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
6 Jan 2020 08:42

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

Read more
6 Nov 2019 11:00

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Read more
6 Nov 2019 09:36

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

Read more
5 Nov 2019 15:13

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

Read more
8 Oct 2019 10:35

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

Read more
8 Oct 2019 09:14

4d Pharma And Merck To Collaborate On Gut Disease Treatments

4d Pharma And Merck To Collaborate On Gut Disease Treatments

Read more
8 Oct 2019 08:30

4D Pharma inks research collaboration agreement with Merck & Co

(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.

Read more
30 Sep 2019 09:33

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

Read more
27 Aug 2019 16:45

4D Pharma Appoints Sangamo Therapeutics Boss Macrae To Board

(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.Macrae currently serves as president & of

Read more
25 Jul 2019 11:26

4d Pharma Picks New Candidate; Encouraging Data On Lead Biotherapeutic

(Alliance News) - 4d Pharma PLC on Thursday announced positive preclinical data on lead biotherapeutic candidate MRx0518 and the identification of a new candidate as well.The new candidate,

Read more
8 Jul 2019 09:29

4d Pharma Begins Live Biotherapeutics Asthma Programme

(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.The double-blind, placebo-controlled study will enrol 90

Read more
13 Jun 2019 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Friday 14 JuneMP Evans GroupSerabi GoldMonday 17 JuneChallenger 18

Read more
30 May 2019 14:26

DIRECTOR DEALINGS: 4d Pharma Chair Buys GBP15,000 In Shares

LONDON (Alliance News) - 4d Pharma PLC on Thursday said that Chair David Norwood acquired 15,000 shares in the company.On Wednesday, Norwood bought the shares at 100.00 pence each for a of

Read more
21 May 2019 11:27

4D Pharma losses widen as it spends cash on development activities

(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.

Read more
21 May 2019 10:29

4d Pharma Annual Loss Widens On Live Biotherapeutic Development Costs

LONDON (Alliance News) - 4d Pharma PLC on Tuesday said its loss widened in 2018 on research and development costs as it continued to develop its live biotherapeutic products, which contain living

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.